Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated:  5/14/2012
Clinical Research Facility
mi
from
New York, NY
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated: 5/14/2012
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated:  5/14/2012
Clinical Research Facility
mi
from
Ashville, NC
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated: 5/14/2012
Clinical Research Facility
mi
from
Ashville, NC
Click here to add this to my saved trials
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated:  5/14/2012
Clinical Research Facility
mi
from
Cleveland, OH
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated: 5/14/2012
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated:  5/14/2012
Clinical Research Facility
mi
from
Philadelphia, PA
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated: 5/14/2012
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated:  5/14/2012
Clinical Research Facility
mi
from
Chattanooga, TN
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated: 5/14/2012
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated:  5/14/2012
Clinical Research Facility
mi
from
Dallas, TX
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated: 5/14/2012
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated:  5/14/2012
Clinical Research Facility
mi
from
Salt Lake City, UT
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated: 5/14/2012
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated:  5/14/2012
Clinical Research Facility
mi
from
Norfolk, VA
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated: 5/14/2012
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated:  5/14/2012
Clinical Research Facility
mi
from
Seattle, WA
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated: 5/14/2012
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Loading Vancomycin Doses in the Emergency Department
A Randomized Prospective Study of Vancomycin Dosing in the Emergency Department: Will a Loading Dose of 30mg/kg Lead to a More Rapid Attainment of Therapeutic Levels?
Status: Enrolling
Updated:  5/29/2012
Chrisitana Care Health System-Christiana Hospital
mi
from
Newark, DE
Loading Vancomycin Doses in the Emergency Department
A Randomized Prospective Study of Vancomycin Dosing in the Emergency Department: Will a Loading Dose of 30mg/kg Lead to a More Rapid Attainment of Therapeutic Levels?
Status: Enrolling
Updated: 5/29/2012
Chrisitana Care Health System-Christiana Hospital
mi
from
Newark, DE
Click here to add this to my saved trials
Earset Healthy Volunteer Study
Performance of the Acclarent Iontophoresis System With Earset (IPSES) in Healthy Volunteers
Status: Enrolling
Updated:  5/31/2012
CEI Medical Group
mi
from
East Palo Alto, CA
Earset Healthy Volunteer Study
Performance of the Acclarent Iontophoresis System With Earset (IPSES) in Healthy Volunteers
Status: Enrolling
Updated: 5/31/2012
CEI Medical Group
mi
from
East Palo Alto, CA
Click here to add this to my saved trials
Study of Rifaximin in Minimal Hepatic Encephalopathy
Effect of Rifaximin Therapy on Brain Activation in Patients With Minimal Hepatic Encephalopathy Using Functional MR, MR Spectroscopy and Diffusion Tensor Imaging: a Prospective Trial
Status: Enrolling
Updated:  6/1/2012
Hunter Holmes McGuire VA Medical Center
mi
from
Richmond, VA
Study of Rifaximin in Minimal Hepatic Encephalopathy
Effect of Rifaximin Therapy on Brain Activation in Patients With Minimal Hepatic Encephalopathy Using Functional MR, MR Spectroscopy and Diffusion Tensor Imaging: a Prospective Trial
Status: Enrolling
Updated: 6/1/2012
Hunter Holmes McGuire VA Medical Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Use of Abbott RealTime CT/NG to Detect Chlamydia Trachomatis [CT] & Neisseria Gonorrhoeae [NG] in Men Who Have Sex With Men [MSM]
Evaluation of Abbott RealTime CT/NG for the Detection of Chlamydia Trachomatis [CT] & Neisseria Gonorrhoeae [NG] From the Pharynx, Rectum & Urethra of Men Who Have Sex With Men [MSM]
Status: Enrolling
Updated:  6/6/2012
University of California - San Francisco
mi
from
San Francisco, CA
Use of Abbott RealTime CT/NG to Detect Chlamydia Trachomatis [CT] & Neisseria Gonorrhoeae [NG] in Men Who Have Sex With Men [MSM]
Evaluation of Abbott RealTime CT/NG for the Detection of Chlamydia Trachomatis [CT] & Neisseria Gonorrhoeae [NG] From the Pharynx, Rectum & Urethra of Men Who Have Sex With Men [MSM]
Status: Enrolling
Updated: 6/6/2012
University of California - San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Use of Abbott RealTime CT/NG to Detect Chlamydia Trachomatis [CT] & Neisseria Gonorrhoeae [NG] in Men Who Have Sex With Men [MSM]
Evaluation of Abbott RealTime CT/NG for the Detection of Chlamydia Trachomatis [CT] & Neisseria Gonorrhoeae [NG] From the Pharynx, Rectum & Urethra of Men Who Have Sex With Men [MSM]
Status: Enrolling
Updated:  6/6/2012
SF City Clinic
mi
from
San Francisco, CA
Use of Abbott RealTime CT/NG to Detect Chlamydia Trachomatis [CT] & Neisseria Gonorrhoeae [NG] in Men Who Have Sex With Men [MSM]
Evaluation of Abbott RealTime CT/NG for the Detection of Chlamydia Trachomatis [CT] & Neisseria Gonorrhoeae [NG] From the Pharynx, Rectum & Urethra of Men Who Have Sex With Men [MSM]
Status: Enrolling
Updated: 6/6/2012
SF City Clinic
mi
from
San Francisco, CA
Click here to add this to my saved trials
Glutathione and Health With Post-Polio Syndrome
Oral Glutathione and Health Outcomes Among Persons With Post-Polio Syndrome
Status: Enrolling
Updated:  6/8/2012
University of Michigan
mi
from
Ann Arbor, MI
Glutathione and Health With Post-Polio Syndrome
Oral Glutathione and Health Outcomes Among Persons With Post-Polio Syndrome
Status: Enrolling
Updated: 6/8/2012
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Probiotic Lactobacillus GG (LGG) in Patients With Minimal Hepatic Encephalopathy
Probiotic LGG in Patients With Minimal Hepatic Encephalopathy
Status: Enrolling
Updated:  6/19/2012
Virginia Commonwealth University
mi
from
Richmond, VA
Probiotic Lactobacillus GG (LGG) in Patients With Minimal Hepatic Encephalopathy
Probiotic LGG in Patients With Minimal Hepatic Encephalopathy
Status: Enrolling
Updated: 6/19/2012
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Effectiveness of Carbon Filters to Reduce the Anesthetic Gas Concentration in an Anesthetized Patient
Effectiveness of Carbon Filters to Reduce the Anesthetic Gas Concentration in an Anesthetized Patient
Status: Enrolling
Updated:  6/19/2012
Johns Hopkins Hosp
mi
from
Baltimore, MD
Effectiveness of Carbon Filters to Reduce the Anesthetic Gas Concentration in an Anesthetized Patient
Effectiveness of Carbon Filters to Reduce the Anesthetic Gas Concentration in an Anesthetized Patient
Status: Enrolling
Updated: 6/19/2012
Johns Hopkins Hosp
mi
from
Baltimore, MD
Click here to add this to my saved trials
HIV Prevention Program for African American Teen Males
A Brief, Clinic-Based, HIV Prevention Program for African American Teen Males
Status: Enrolling
Updated:  6/24/2012
Adolescent Medicine Program, LSU School of Medicine
mi
from
New Orleans, LA
HIV Prevention Program for African American Teen Males
A Brief, Clinic-Based, HIV Prevention Program for African American Teen Males
Status: Enrolling
Updated: 6/24/2012
Adolescent Medicine Program, LSU School of Medicine
mi
from
New Orleans, LA
Click here to add this to my saved trials
Evaluate Tolerability of Myfortic®/Simulect® and Tacrolimus Without Steroids in Three Patient Populations
Study to Evaluate Tolerability of Myfortic With Simulect Induction and Tacrolimus Without Steroids in Three Patient Populations; 1: Kidney/Pancreas Transplants,2: Diabetic Kidney Transplants, and 3: Non-diabetic Kidney Transplants
Status: Enrolling
Updated:  6/25/2012
University of Texas Medical Branch
mi
from
Galveston, TX
Evaluate Tolerability of Myfortic®/Simulect® and Tacrolimus Without Steroids in Three Patient Populations
Study to Evaluate Tolerability of Myfortic With Simulect Induction and Tacrolimus Without Steroids in Three Patient Populations; 1: Kidney/Pancreas Transplants,2: Diabetic Kidney Transplants, and 3: Non-diabetic Kidney Transplants
Status: Enrolling
Updated: 6/25/2012
University of Texas Medical Branch
mi
from
Galveston, TX
Click here to add this to my saved trials
Demonstration of Near Zero Antibiotic Prescribing for Acute Bronchitis
Demonstration of Near Zero Antibiotic Prescribing for Acute Bronchitis
Status: Enrolling
Updated:  6/27/2012
Brigham and Women's Hospital Jen Center for Primary Care
mi
from
Boston, MA
Demonstration of Near Zero Antibiotic Prescribing for Acute Bronchitis
Demonstration of Near Zero Antibiotic Prescribing for Acute Bronchitis
Status: Enrolling
Updated: 6/27/2012
Brigham and Women's Hospital Jen Center for Primary Care
mi
from
Boston, MA
Click here to add this to my saved trials
Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-allergic Rhinitis in Subjects With Persistent Nasal Congestion
Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-allergic Rhinitis in Subjects With Persistent Nasal Congestion
Status: Enrolling
Updated:  6/27/2012
USF
mi
from
Tampa, FL
Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-allergic Rhinitis in Subjects With Persistent Nasal Congestion
Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-allergic Rhinitis in Subjects With Persistent Nasal Congestion
Status: Enrolling
Updated: 6/27/2012
USF
mi
from
Tampa, FL
Click here to add this to my saved trials
Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy
Biomarkers of Immune Function as Predictors of Head and Neck Squamous Cell Carcinoma (HNSCC) in Response to Therapy
Status: Enrolling
Updated:  7/9/2012
The Mount Sinai Medical Center, Otolaryngology - Head and Neck Surgery
mi
from
New York, NY
Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy
Biomarkers of Immune Function as Predictors of Head and Neck Squamous Cell Carcinoma (HNSCC) in Response to Therapy
Status: Enrolling
Updated: 7/9/2012
The Mount Sinai Medical Center, Otolaryngology - Head and Neck Surgery
mi
from
New York, NY
Click here to add this to my saved trials
Use of Platelet-Rich Plasma (PRP) and Platelet-Poor Plasma (PPP) to Prevent Infection and Delayed Wound Healing
Use of Platelet-Rich Plasma (PRP) and Platelet-Poor Plasma (PPP) to Prevent Infection and Delayed Wound Healing After Elective Foot and Ankle Surgery in Healthy Adults
Status: Enrolling
Updated:  7/11/2012
UHZ Sports Medicine Institute
mi
from
Coral Gables, FL
Use of Platelet-Rich Plasma (PRP) and Platelet-Poor Plasma (PPP) to Prevent Infection and Delayed Wound Healing
Use of Platelet-Rich Plasma (PRP) and Platelet-Poor Plasma (PPP) to Prevent Infection and Delayed Wound Healing After Elective Foot and Ankle Surgery in Healthy Adults
Status: Enrolling
Updated: 7/11/2012
UHZ Sports Medicine Institute
mi
from
Coral Gables, FL
Click here to add this to my saved trials
Fidaxomicin to Prevent Clostridium Difficile Colonization
The Effect of a Twice Daily, 200 mg Dose of Oral Fidaxomicin Compared to Placebo on Risk of Acquiring C. Difficile and Developing C. Difficile Infection (CDI) in High Risk Patients
Status: Enrolling
Updated:  7/19/2012
Washington University
mi
from
St. Louis, MO
Fidaxomicin to Prevent Clostridium Difficile Colonization
The Effect of a Twice Daily, 200 mg Dose of Oral Fidaxomicin Compared to Placebo on Risk of Acquiring C. Difficile and Developing C. Difficile Infection (CDI) in High Risk Patients
Status: Enrolling
Updated: 7/19/2012
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
ACT-179811 in Patients With Clostridium Difficile Infection
Multi-center, Double-blind, Randomized, Active Reference, Parallel Group Study to Evaluate the Efficacy, Safety & Tolerability of 3 Doses of ACT-179811 in Subjects With Clostridium Difficile Infection
Status: Enrolling
Updated:  7/27/2012
Clinical Investigative Site 6902
mi
from
Newark, DE
ACT-179811 in Patients With Clostridium Difficile Infection
Multi-center, Double-blind, Randomized, Active Reference, Parallel Group Study to Evaluate the Efficacy, Safety & Tolerability of 3 Doses of ACT-179811 in Subjects With Clostridium Difficile Infection
Status: Enrolling
Updated: 7/27/2012
Clinical Investigative Site 6902
mi
from
Newark, DE
Click here to add this to my saved trials
ACT-179811 in Patients With Clostridium Difficile Infection
Multi-center, Double-blind, Randomized, Active Reference, Parallel Group Study to Evaluate the Efficacy, Safety & Tolerability of 3 Doses of ACT-179811 in Subjects With Clostridium Difficile Infection
Status: Enrolling
Updated:  7/27/2012
Clinical Investigative Site 6919
mi
from
Jacksonville, FL
ACT-179811 in Patients With Clostridium Difficile Infection
Multi-center, Double-blind, Randomized, Active Reference, Parallel Group Study to Evaluate the Efficacy, Safety & Tolerability of 3 Doses of ACT-179811 in Subjects With Clostridium Difficile Infection
Status: Enrolling
Updated: 7/27/2012
Clinical Investigative Site 6919
mi
from
Jacksonville, FL
Click here to add this to my saved trials
ACT-179811 in Patients With Clostridium Difficile Infection
Multi-center, Double-blind, Randomized, Active Reference, Parallel Group Study to Evaluate the Efficacy, Safety & Tolerability of 3 Doses of ACT-179811 in Subjects With Clostridium Difficile Infection
Status: Enrolling
Updated:  7/27/2012
Clinical Investigative Site 6938
mi
from
Orlando, FL
ACT-179811 in Patients With Clostridium Difficile Infection
Multi-center, Double-blind, Randomized, Active Reference, Parallel Group Study to Evaluate the Efficacy, Safety & Tolerability of 3 Doses of ACT-179811 in Subjects With Clostridium Difficile Infection
Status: Enrolling
Updated: 7/27/2012
Clinical Investigative Site 6938
mi
from
Orlando, FL
Click here to add this to my saved trials
ACT-179811 in Patients With Clostridium Difficile Infection
Multi-center, Double-blind, Randomized, Active Reference, Parallel Group Study to Evaluate the Efficacy, Safety & Tolerability of 3 Doses of ACT-179811 in Subjects With Clostridium Difficile Infection
Status: Enrolling
Updated:  7/27/2012
Clinical Investigative Site 6930
mi
from
Decatur, GA
ACT-179811 in Patients With Clostridium Difficile Infection
Multi-center, Double-blind, Randomized, Active Reference, Parallel Group Study to Evaluate the Efficacy, Safety & Tolerability of 3 Doses of ACT-179811 in Subjects With Clostridium Difficile Infection
Status: Enrolling
Updated: 7/27/2012
Clinical Investigative Site 6930
mi
from
Decatur, GA
Click here to add this to my saved trials
ACT-179811 in Patients With Clostridium Difficile Infection
Multi-center, Double-blind, Randomized, Active Reference, Parallel Group Study to Evaluate the Efficacy, Safety & Tolerability of 3 Doses of ACT-179811 in Subjects With Clostridium Difficile Infection
Status: Enrolling
Updated:  7/27/2012
Clinical Investigative Site 6935
mi
from
Marietta, GA
ACT-179811 in Patients With Clostridium Difficile Infection
Multi-center, Double-blind, Randomized, Active Reference, Parallel Group Study to Evaluate the Efficacy, Safety & Tolerability of 3 Doses of ACT-179811 in Subjects With Clostridium Difficile Infection
Status: Enrolling
Updated: 7/27/2012
Clinical Investigative Site 6935
mi
from
Marietta, GA
Click here to add this to my saved trials
ACT-179811 in Patients With Clostridium Difficile Infection
Multi-center, Double-blind, Randomized, Active Reference, Parallel Group Study to Evaluate the Efficacy, Safety & Tolerability of 3 Doses of ACT-179811 in Subjects With Clostridium Difficile Infection
Status: Enrolling
Updated:  7/27/2012
Clinical Investigative Site 6915
mi
from
Idaho Falls, ID
ACT-179811 in Patients With Clostridium Difficile Infection
Multi-center, Double-blind, Randomized, Active Reference, Parallel Group Study to Evaluate the Efficacy, Safety & Tolerability of 3 Doses of ACT-179811 in Subjects With Clostridium Difficile Infection
Status: Enrolling
Updated: 7/27/2012
Clinical Investigative Site 6915
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
ACT-179811 in Patients With Clostridium Difficile Infection
Multi-center, Double-blind, Randomized, Active Reference, Parallel Group Study to Evaluate the Efficacy, Safety & Tolerability of 3 Doses of ACT-179811 in Subjects With Clostridium Difficile Infection
Status: Enrolling
Updated:  7/27/2012
Clinical Investigative Site 6906
mi
from
Chicago, IL
ACT-179811 in Patients With Clostridium Difficile Infection
Multi-center, Double-blind, Randomized, Active Reference, Parallel Group Study to Evaluate the Efficacy, Safety & Tolerability of 3 Doses of ACT-179811 in Subjects With Clostridium Difficile Infection
Status: Enrolling
Updated: 7/27/2012
Clinical Investigative Site 6906
mi
from
Chicago, IL
Click here to add this to my saved trials
ACT-179811 in Patients With Clostridium Difficile Infection
Multi-center, Double-blind, Randomized, Active Reference, Parallel Group Study to Evaluate the Efficacy, Safety & Tolerability of 3 Doses of ACT-179811 in Subjects With Clostridium Difficile Infection
Status: Enrolling
Updated:  7/27/2012
Clinical Investigative Site 6917
mi
from
Boston, MA
ACT-179811 in Patients With Clostridium Difficile Infection
Multi-center, Double-blind, Randomized, Active Reference, Parallel Group Study to Evaluate the Efficacy, Safety & Tolerability of 3 Doses of ACT-179811 in Subjects With Clostridium Difficile Infection
Status: Enrolling
Updated: 7/27/2012
Clinical Investigative Site 6917
mi
from
Boston, MA
Click here to add this to my saved trials
ACT-179811 in Patients With Clostridium Difficile Infection
Multi-center, Double-blind, Randomized, Active Reference, Parallel Group Study to Evaluate the Efficacy, Safety & Tolerability of 3 Doses of ACT-179811 in Subjects With Clostridium Difficile Infection
Status: Enrolling
Updated:  7/27/2012
Clinical Investigative Site 6936
mi
from
Royal Oak, MI
ACT-179811 in Patients With Clostridium Difficile Infection
Multi-center, Double-blind, Randomized, Active Reference, Parallel Group Study to Evaluate the Efficacy, Safety & Tolerability of 3 Doses of ACT-179811 in Subjects With Clostridium Difficile Infection
Status: Enrolling
Updated: 7/27/2012
Clinical Investigative Site 6936
mi
from
Royal Oak, MI
Click here to add this to my saved trials
ACT-179811 in Patients With Clostridium Difficile Infection
Multi-center, Double-blind, Randomized, Active Reference, Parallel Group Study to Evaluate the Efficacy, Safety & Tolerability of 3 Doses of ACT-179811 in Subjects With Clostridium Difficile Infection
Status: Enrolling
Updated:  7/27/2012
Clinical Investigative Site 6903
mi
from
Columbus, OH
ACT-179811 in Patients With Clostridium Difficile Infection
Multi-center, Double-blind, Randomized, Active Reference, Parallel Group Study to Evaluate the Efficacy, Safety & Tolerability of 3 Doses of ACT-179811 in Subjects With Clostridium Difficile Infection
Status: Enrolling
Updated: 7/27/2012
Clinical Investigative Site 6903
mi
from
Columbus, OH
Click here to add this to my saved trials
ACT-179811 in Patients With Clostridium Difficile Infection
Multi-center, Double-blind, Randomized, Active Reference, Parallel Group Study to Evaluate the Efficacy, Safety & Tolerability of 3 Doses of ACT-179811 in Subjects With Clostridium Difficile Infection
Status: Enrolling
Updated:  7/27/2012
Clinical Investigative Site 6914
mi
from
Houston, TX
ACT-179811 in Patients With Clostridium Difficile Infection
Multi-center, Double-blind, Randomized, Active Reference, Parallel Group Study to Evaluate the Efficacy, Safety & Tolerability of 3 Doses of ACT-179811 in Subjects With Clostridium Difficile Infection
Status: Enrolling
Updated: 7/27/2012
Clinical Investigative Site 6914
mi
from
Houston, TX
Click here to add this to my saved trials
Sirolimus, Tacrolimus, Anti-Thymocyte Globulin, and Rituximab in Preventing Graft-versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
A Pilot Phase II Study of Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  7/30/2012
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Sirolimus, Tacrolimus, Anti-Thymocyte Globulin, and Rituximab in Preventing Graft-versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
A Pilot Phase II Study of Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 7/30/2012
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
A Pilot Study of Reduced Intensity Conditioning in Pediatric Patients <21 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood Transplantation
Status: Enrolling
Updated:  8/5/2012
Duke University Medical Center Pediatric Blood and Marrow Transplant Program
mi
from
Durham, NC
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
A Pilot Study of Reduced Intensity Conditioning in Pediatric Patients <21 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood Transplantation
Status: Enrolling
Updated: 8/5/2012
Duke University Medical Center Pediatric Blood and Marrow Transplant Program
mi
from
Durham, NC
Click here to add this to my saved trials
Study of the Performance of the KeyPath MRSA/MSSA Blood Culture Test - BTA
Prospective Study Into the Performance of the KeyPathtm MRSA/MSSA Blood Culture Test - BTA
Status: Enrolling
Updated:  8/7/2012
University of Arizona, Infectious Disease Research
mi
from
Tuscon, AZ
Study of the Performance of the KeyPath MRSA/MSSA Blood Culture Test - BTA
Prospective Study Into the Performance of the KeyPathtm MRSA/MSSA Blood Culture Test - BTA
Status: Enrolling
Updated: 8/7/2012
University of Arizona, Infectious Disease Research
mi
from
Tuscon, AZ
Click here to add this to my saved trials
Study of the Performance of the KeyPath MRSA/MSSA Blood Culture Test - BTA
Prospective Study Into the Performance of the KeyPathtm MRSA/MSSA Blood Culture Test - BTA
Status: Enrolling
Updated:  8/7/2012
UCLA Clinical Laboratory
mi
from
Los Angeles, CA
Study of the Performance of the KeyPath MRSA/MSSA Blood Culture Test - BTA
Prospective Study Into the Performance of the KeyPathtm MRSA/MSSA Blood Culture Test - BTA
Status: Enrolling
Updated: 8/7/2012
UCLA Clinical Laboratory
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of the Performance of the KeyPath MRSA/MSSA Blood Culture Test - BTA
Prospective Study Into the Performance of the KeyPathtm MRSA/MSSA Blood Culture Test - BTA
Status: Enrolling
Updated:  8/7/2012
Medical University of South Carolina
mi
from
Charleston, SC
Study of the Performance of the KeyPath MRSA/MSSA Blood Culture Test - BTA
Prospective Study Into the Performance of the KeyPathtm MRSA/MSSA Blood Culture Test - BTA
Status: Enrolling
Updated: 8/7/2012
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated:  8/7/2012
Stanford Univ Med Ctr
mi
from
Stanford, CA
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated: 8/7/2012
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated:  8/7/2012
Northwestern University Dept of Dermatology
mi
from
Chicago, IL
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated: 8/7/2012
Northwestern University Dept of Dermatology
mi
from
Chicago, IL
Click here to add this to my saved trials
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated:  8/7/2012
Columbia University, Dept of Dermatology
mi
from
New York, NY
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated: 8/7/2012
Columbia University, Dept of Dermatology
mi
from
New York, NY
Click here to add this to my saved trials
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated:  8/7/2012
NYU Medical Center Dept. of Dermatology
mi
from
New York, NY
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated: 8/7/2012
NYU Medical Center Dept. of Dermatology
mi
from
New York, NY
Click here to add this to my saved trials
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated:  8/7/2012
Duke Univ Med Ctr
mi
from
Durham, NC
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated: 8/7/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated:  8/7/2012
Oklahoma University
mi
from
Tulsa, OK
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated: 8/7/2012
Oklahoma University
mi
from
Tulsa, OK
Click here to add this to my saved trials
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated:  8/7/2012
Fox Chase Cancer Center
mi
from
Philadelphia, PA
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated: 8/7/2012
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated:  8/7/2012
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated: 8/7/2012
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated:  8/7/2012
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated: 8/7/2012
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated:  8/7/2012
Utah Clinical Trials
mi
from
Salt Lake City, UT
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated: 8/7/2012
Utah Clinical Trials
mi
from
Salt Lake City, UT
Click here to add this to my saved trials